Kisspeptin-10
Also referenced as: KISS1R agonist
A bioactive kisspeptin fragment studied in human reproductive endocrine physiology.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Investigational
No FDA-approved kisspeptin-10 product or indication; investigational endocrine research only.
- Human data
- Limited
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A bioactive kisspeptin fragment studied in human reproductive endocrine physiology.
No FDA-approved kisspeptin-10 product or indication; investigational endocrine research only.
Kisspeptin-54 findings cannot automatically be assigned to kisspeptin-10; short hormone responses are not durable treatment outcomes.
Why It's Being Studied
- GnRH signalling
- Acute LH response
- Reproductive research
Mechanism of Action
KISS1R activation acts upstream of GnRH release and can acutely stimulate LH secretion.
KISS1R activation acts upstream of GnRH release and can acutely stimulate LH secretion. Kisspeptin-54 findings cannot automatically be assigned to kisspeptin-10; short hormone responses are not durable treatment outcomes.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- GnRH signalling
- Acute LH response
- Reproductive research
- Injectable clinical research
Evidence Summary
Small human studies demonstrate acute endocrine responses, not established infertility treatment or durable sexual or testosterone benefits.
Higher tiers carry more weight. Filled tiers have evidence for Kisspeptin-10; tap to read it.
- Small human studies demonstrate acute endocrine responses, not established infertility treatment or durable sexual or testosterone benefits.
1 cited sources.
- Clinical trial1
Human clinical evidence
- Small human studies demonstrate acute endocrine responses, not established infertility treatment or durable sexual or testosterone benefits.
Reported Adverse Events in Research
- Long-term administration safety and clinically meaningful outcome effects remain insufficiently characterized.
Limitations of Current Evidence
- Kisspeptin-54 findings cannot automatically be assigned to kisspeptin-10; short hormone responses are not durable treatment outcomes.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Kisspeptin-10 | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Investigational | FDA Approved for Specific Indication |
| Human data | Limited | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Injectable clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Clinical trial
Kisspeptin-10 — clinical trial